Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies.  We are actively applying the platform internally and with partners across a range of disease indications.

In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Polaris Partners

EDBI

Seeds Capital

ClavystBio

Invus

Coronet Ventures

WI Harper Group

6 Dimensions Capital

Baidu Ventures

Vectr

Nest.Bio Ventures

Goodman Capital

DHVC

Engine Biosciences

Engine Bio is honored to be recognised by Singapore Minister of Trade and Industry Gan Kim Yong for our work to pioneer Al-enabled therapeutics and biomarkers for precision medicine. We are very encouraged by our progress and strong supporters, and we are motivated to keep pushing to deliver impact in healthcare and pharmaceuticals!

(See 13:40 for Minister Gan’s remarks on Engine Bio):

Jeffrey Lu, CEO and co-founder of precision medicines company Engine Biosciences, foresaw "accelerating adoption of Al in biopharma R&D across the value chain. Not only has the 2023 Al boom opened the world's eyes dramatically, application-specific tools that have been built rigorously over the past several years in uses cases like small-molecule screening, target selection, protein design, and patient stratification are reaching greater maturity in technology validation and operational deployment."

Thank you Minister Gan Kim Yong and Ministry of Trade and Industry (Singapore)  for giving us the privilege of hosting you and your colleagues from Enterprise Singapore  and Singapore Economic Development Board (EDB) at our Silicon Valley office!  We enjoyed discussing the opportunities around #precisionmedicine, and Engine Biosciences’ approach by identifying targets, drugs, and biomarkers coming out of our R&D efforts in both Singapore and California.

Atomwise is a leading AI-driven drug discovery company that uses artificial intelligence to predict and analyze molecular structures for drug development.

Atomwise

Insitro is a biotech company that focuses on applying machine learning and data analysis to drug discovery and development processes.

Insitro

Owkin is a company that specializes in using machine learning and AI to analyze medical data for drug discovery and development.

Owkin

Enveda Biosciences is a biotech company that combines biosciences and artificial intelligence to discover and develop new therapeutics.

Enveda Biosciences

Brightseed is a biosciences company that utilizes artificial intelligence to discover and develop novel bioactive compounds for various applications.

Brightseed

Biomia is a company that applies AI and biosciences to identify and develop potential drug candidates for various therapeutic areas.

Biomia

Montai Health is a healthcare company that leverages AI and biosciences to discover and develop new therapeutic solutions for medical challenges.

Montai Health

Seismic Therapeutic is an AI-driven drug discovery company that specializes in immunology drug discovery using advanced machine learning techniques.

Seismic Therapeutic

Pathos is a company that focuses on AI-driven precision medicine, utilizing advanced data analysis and machine learning for drug discovery and development.

Pathos

Polaris Quantum Biotech is a biotech company that has developed an AI-powered platform for drug discovery and molecular design, focusing on accelerating the drug development process.

Polaris Quantum Biotech

Engine Biosciences is a technology-enabled drug discovery company that leverages its proprietary platform to discover and develop new therapeutics. The company integrates biology and technology to map disease circuitry and identify potential drug candidates more efficiently.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 15, 2024 12:36 PM	54361f39
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 15, 2024 12:36 PM	62a47f99
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ENGINEBIO

Engine Biosciences